Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Domingo Pascual-Figal

Showing results (1-10 of 107) with videos related to

Pageof 11
Sort By:
European Journal of Heart Failure|June 27, 2018
The misperception of 'stable' heart failureDomingo Pascual-Figal, Antoni Bayes-Genis
European Heart Journal|May 23, 2023
Making STRONGer the transition phase: personalized GDMT through NT-proBNP monitoringAntoni Bayes-Genis, Domingo Pascual-Figal
Journal of Cardiovascular Translational Research|June 17, 2020
The Challenging and Amazing Field of Sports CardiologyM Carmen Adamuz, Domingo Pascual Figal
Frontiers in Cardiovascular Medicine|September 24, 2024
Looking for the ideal medication for heart failure with reduced ejection fraction: a narrative reviewDomingo Pascual-Figal, Antoni Bayes-Genis
European Journal of Preventive Cardiology|February 21, 2021
The pre-HFpEF stage: a new entity that requires proper phenotyping for better managementAntoni Bayes-Genis, Domingo Pascual-Figal, Julio Núñez
European Heart Journal|February 6, 2024
Clonal haematopoiesis and cardiac arrythmias: rhythm-altering mutationsMaría A Zuriaga, Domingo Pascual-Figal, José J Fuster
The American Journal of Cardiology|February 12, 2015
ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus PanelJames L Januzzi, Domingo Pascual-Figal, Lori B Daniels
European Journal of Heart Failure|October 4, 2023
Personalizing anti-inflammatory therapy in heart failure: A new wayDomingo Pascual-Figal, Jose Javier Fuster, Antoni Bayes-Genis
Revista Espanola De Cardiologia (English Ed.)|April 21, 2023
Circulating ST2, from biomarker to pathogenic mediatorDomingo Pascual-Figal, Antonio Lax, María Carmen Asensio López
Journal of Clinical Medicine|November 14, 2023
Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on DapagliflozinCarlos Escobar, Domingo Pascual-Figal, Luis Manzano, et al.
Pageof 11

Showing results (1-10 of 107) with videos related to

Sort By:
Pageof 11
European Journal of Heart Failure|June 27, 2018
The misperception of 'stable' heart failureDomingo Pascual-Figal, Antoni Bayes-Genis
European Heart Journal|May 23, 2023
Making STRONGer the transition phase: personalized GDMT through NT-proBNP monitoringAntoni Bayes-Genis, Domingo Pascual-Figal
Journal of Cardiovascular Translational Research|June 17, 2020
The Challenging and Amazing Field of Sports CardiologyM Carmen Adamuz, Domingo Pascual Figal
Frontiers in Cardiovascular Medicine|September 24, 2024
Looking for the ideal medication for heart failure with reduced ejection fraction: a narrative reviewDomingo Pascual-Figal, Antoni Bayes-Genis
European Journal of Preventive Cardiology|February 21, 2021
The pre-HFpEF stage: a new entity that requires proper phenotyping for better managementAntoni Bayes-Genis, Domingo Pascual-Figal, Julio Núñez
European Heart Journal|February 6, 2024
Clonal haematopoiesis and cardiac arrythmias: rhythm-altering mutationsMaría A Zuriaga, Domingo Pascual-Figal, José J Fuster
The American Journal of Cardiology|February 12, 2015
ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus PanelJames L Januzzi, Domingo Pascual-Figal, Lori B Daniels
European Journal of Heart Failure|October 4, 2023
Personalizing anti-inflammatory therapy in heart failure: A new wayDomingo Pascual-Figal, Jose Javier Fuster, Antoni Bayes-Genis
Revista Espanola De Cardiologia (English Ed.)|April 21, 2023
Circulating ST2, from biomarker to pathogenic mediatorDomingo Pascual-Figal, Antonio Lax, María Carmen Asensio López
Journal of Clinical Medicine|November 14, 2023
Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on DapagliflozinCarlos Escobar, Domingo Pascual-Figal, Luis Manzano, et al.
Pageof 11